These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 21883034)

  • 1. Linagliptin for the treatment of type 2 diabetes.
    Del Prato S
    Expert Opin Pharmacother; 2011 Dec; 12(17):2759-62. PubMed ID: 21883034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
    Scheen AJ
    Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug.
    Idris I; Donnelly R
    Diabetes Obes Metab; 2007 Mar; 9(2):153-65. PubMed ID: 17300591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK
    Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.
    Del Prato S
    Int J Clin Pract Suppl; 2007 Aug; (154):38-48. PubMed ID: 17593276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.
    Herman GA; Stein PP; Thornberry NA; Wagner JA
    Clin Pharmacol Ther; 2007 May; 81(5):761-7. PubMed ID: 17392725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
    Choy M; Lam S
    Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review.
    Deacon CF
    Diabetes Obes Metab; 2011 Jan; 13(1):7-18. PubMed ID: 21114598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
    Neumiller JJ
    Clin Ther; 2011 May; 33(5):528-76. PubMed ID: 21665041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
    Neumiller JJ; Wood L; Campbell RK
    Pharmacotherapy; 2010 May; 30(5):463-84. PubMed ID: 20411998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Gallwitz B
    IDrugs; 2008 Dec; 11(12):906-17. PubMed ID: 19051153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
    Langley AK; Suffoletta TJ; Jennings HR
    Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newly approved and promising antidiabetic agents.
    Combettes M; Kargar C
    Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus.
    Rosenstock J; Zinman B
    Curr Opin Endocrinol Diabetes Obes; 2007 Apr; 14(2):98-107. PubMed ID: 17940427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DPP-4 inhibitors and their potential role in the management of type 2 diabetes.
    Barnett A
    Int J Clin Pract; 2006 Nov; 60(11):1454-70. PubMed ID: 17073841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with T2D trial.
    Nath B; Suvarna VR
    Perspect Clin Res; 2020; 11(1):44-46. PubMed ID: 32154149
    [No Abstract]   [Full Text] [Related]  

  • 17. Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis.
    Kim JY; Yang S; Lee JI; Chang MJ
    PLoS One; 2016; 11(4):e0153502. PubMed ID: 27078018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linagliptin: from bench to bedside.
    Doupis J
    Drug Des Devel Ther; 2014; 8():431-46. PubMed ID: 24851042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Linagliptin: A thorough Characterization beyond Its Clinical Efficacy.
    Sortino MA; Sinagra T; Canonico PL
    Front Endocrinol (Lausanne); 2013; 4():16. PubMed ID: 23550180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes.
    Hoimark L; Laursen T; Rungby J
    Diabetes Metab Syndr Obes; 2012; 5():295-302. PubMed ID: 22952411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.